Developmental changes in gamma-aminobutyric acid levels in attention-deficit/hyperactivity disorder

Translational Psychiatry

Volumn 5, Issue 6, 2015, Pages

  Bollmann, S ^a,b,c   Ghisleni, C ^a,b   Poil, S S ^a,b   Martin, E ^a,b   Ball, J ^b   Eich Hochli D ^d   Edden, R A E ^e,f   Klaver, P ^a,b   Michels, L ^g   Brandeis, D ^b,h   O'Gorman, R L ^a,b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f KENNEDY KRIEGER INSTITUTE   (United States)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE;

ADULT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FRONTAL CORTEX; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; SUBCORTEX; ADOLESCENT; ADOLESCENT DEVELOPMENT; BRAIN; CASE CONTROL STUDY; CHILD DEVELOPMENT; FRONTAL LOBE; GRAY MATTER; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT; FEMALE; FRONTAL LOBE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; GRAY MATTER; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84941976250     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.79     Document Type: Article

References (54)

1. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20:386-392.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). American Psychiatric Association Press: Washington, DC, USA, 2013.
3. 1H-magnetic resonance spectroscopy study of fronto-striato-thalamic regions. J Neural Transm 2009;116:623-629.
4. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain (1) h magnetic resonance spectra. Neurochem Res 2014;39:1-36.
5. Tritsch NX, Ding JB, Sabatini BL. Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature 2012;490:262-266.
6. Boy F, Evans CJ, Edden RAE, Lawrence AD, Singh KD, Husain M et al. Dorsolateral prefrontal ã-amino butyric acid in men predicts individual differences in rash impulsivity. Biol Psychiatry 2011;70:866-872.
7. Silveri MM, Sneider JT, Crowley DJ, Covell MJ, Acharya D, Rosso IM et al. Frontal lobe ã-aminobutyric acid levels during adolescence: associations with impulsivity and response inhibition. Biol Psychiatry 2013;74:296-304.
8. Courvoisie H, Hooper SR, Fine C, Kwock L, Castillo M. Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. J Neuropsychiatry Clin Neurosci 2004;16:63-69.
9. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M et al. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am J Psychiatry 2006;163:316-318.
10. Carrey NJ, MacMaster FP, Gaudet L, Schmidt MH. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:11-17.
11. MacMaster FP, Carrey N, Sparkes S, Kusumakar V. Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder. Biol Psychiatry 2003;53:184-187.
12. Perlov E, Philipsen A, Matthies S, Drieling T, Maier S, Bubl E et al. Spectroscopic findings in attention-deficit/hyperactivity disorder: review and meta-analysis. World J Biol Psychiatry 2009;10:355-365.
13. 1HMRS study. Clin Neuropharmacol 2003;26:218.
14. Yeo RA, Hill DE, Campbell RA, Vigil J, Petropoulos H, Hart B et al. Proton magnetic resonance spectroscopy investigation of the right frontal lobe in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003;42:303-310.
15. 1H-magnetic resonance spectroscopy study. Brain Dev 2005;27:340-344.
16. Benamor L. (1) H-Magnetic resonance spectroscopy study of stimulant medication effect on brain metabolites in French Canadian children with attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat 2014;10:47-54.
17. Perlov E, Tebarzt van Elst L, Buechert M, Maier S, Matthies S, Ebert D et al. H1-MRspectroscopy of cerebellum in adult attention deficit/hyperactivity disorder. J Psychiatr Res 2010;44:938-943.
18. Perlov E, Philipsen A, Hesslinger B, Buechert M, Ahrendts J, Feige B et al. Reduced cingulate glutamate/glutamine-to-creatine ratios in adult patients with attention deficit/hyperactivity disorder - A magnet resonance spectroscopy study. J Psychiatr Res 2007;41:934-941.
19. Dramsdahl M, Ersland L, Plessen KJ, Haavik J, Hugdahl K, Specht K. Adults with attention-deficit/hyperactivity disorder-a brain magnetic resonance spectroscopy study. Front Psychiatry 2011;2:65.
20. Maltezos S, Horder J, Coghlan S, Skirrow C, O'Gorman R, Lavender TJ et al. Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study. Transl Psychiatry 2014;4:e373.
21. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006;98:641-653.
22. Hancu I, Port J. The case of the missing glutamine. NMR Biomed 2011;24:529-535.
23. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002;159:1944-1946.
24. Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos Trans R Soc Lond B Biol Sci 1999;354:1165-1177.
25. Edden RAE, Crocetti D, Zhu H, Gilbert DL, Mostofsky SH. Reduced GABA concentration in attention-deficit/hyperactivity disorder reduced GABA concentration in ADHD. Arch Gen Psychiatry 2012;69:750-753.
26. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011;168:1154-1163.
27. Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attentiondeficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 2013;70:185-198.
28. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002;288:1740.
29. Delmo C, Weiffenbach O, Stadler C, Poustka F. Diagnostisches Interview Kiddie-Sads-Present and Lifetime Version (K-SADS-PL): 5: Auflage derdeutschen Forschungsversion, erweitert umICD-10-Diagnostik.. Frankfurt, Germany: Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, 2001.
30. Christiansen H, Kis B, Hirsch O, Philipsen A, Henneck M, Panczuk A et al. German validation of the Conners Adult ADHD Rating Scales-self-report (CAARS-S) I: Factor structure and normative data. Eur Psychiatry 2011;26:100-107.
31. Retz-Junginger P, Retz W, Blocher D, Stieglitz R-D, Georg T, Supprian T et al. Reliabilität und Validität der Wender-Utah-Rating-Scale-Kurzform. Nervenarzt 2003;74:987-993.
32. Lidzba K Christiansen H Drechsler R. Conners Skalen zu Aufmerksamkeit und Verhalten - 3. Deutschsprachige Adaptation der Conners, 3rd edition Conners 3. von C. Keith Conners (Vol. in press): Huber: Bern, Germany, 2013.
33. Woerner W, Becker A, Rothenberger A. Normative data and scale properties of the German parent SDQ. Eur Child Adolesc Psychiatry 2004;13:II3-10.
34. Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med 2006;55:1219-1226.
35. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
36. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2013.
37. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer: New York, NY, USA, 2009.
38. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-818.
39. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA 2007;104:19649-19654.
40. Frodl T, Skokauskas N. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr Scand 2012;125:114-126.
41. Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry 2013;74:902-917.
42. Proal E, Reiss PT, Klein RG, Mannuzza S, Gotimer K, Ramos-Olazagasti MA et al. Brain gray matter deficits at 33-year follow-up in adults with attention-deficit/hyperactivity disorder established in childhood. Arch Gen Psychiatry 2011;68:1122-1134.
43. Gao F, Edden RAE, Li M, Puts NAJ, Wang G, Liu C et al. Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage 2013;78:75-82.
44. Aufhaus E, Weber-Fahr W, Sack M, Tunc-Skarka N, Oberthuer G, Hoerst M et al. Absence of changes in GABA concentrations with age and gender in the human anterior cingulate cortex: A MEGA-PRESS study with symmetric editing pulse frequencies for macromolecule suppression. Magn Reson Med 2013;69:317-320.
45. Carrey N, MacMaster FP, Sparkes SJ, Khan SC, Kusumakar V. Glutamatergic Changes with Treatment in Attention Deficit Hyperactivity Disorder: A Preliminary Case Series. J Child Adolesc Psychopharmacol 2002;12:331-336.
46. Sparkes SJ, MacMaster FP, Carrey NC. Proton magnetic resonance spectroscopy and cognitive function in pediatric attention-deficit/hyperactive disorder. Brain Cogn 2004;54:173-175.
47. 1H-magnetic resonance spectroscopy study. Neurosci Lett 2001;315:45-48.
48. 1H-magnetic resonance spectroscopy. Neurosci Lett 2001;304:117-119.
49. Henry P-G, Dautry C, Hantraye P, Bloch G. Brain GABA editing without macromolecule contamination. Magn Reson Med 2001;45:517-520.
50. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002;59:851-858.
51. Taylor M, Murphy SE, Selvaraj S, Wylezinkska M, Jezzard P, Cowen PJ et al. Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 2008;22:473-476.
52. Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 2004;161:368-370.
53. Mullins PG, McGonigle DJ, O'Gorman RL, Puts NAJ, Vidyasagar R, Evans CJ et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 2014;86:43-52.
54. O'Gorman RL, Michels L, Edden RAE, Murdoch JB, Martin E. In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects. J Magn Reson Imaging 2011;33:1262-1267.